| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| 10g | |||
| Other Sizes |
Purity: ≥98%
Fluorometholone (also known as NSC 47438) is a synthetic corticosteroid, commonly used as eye drops in the treatment of steroid responsive inflammatory conditions of the eye. Hourly topical administration of the drug suspension produces an average reduction of 46.8% in the polymorphonuclear leukocytes invading the corneal stroma. In the cornea, fluorometholone acetate appears to have a greater efficacy, as compared to fluorometholone alcohol, for reducing the number of leukocytes invading that tissue following an inflammatory stimulus.
| ln Vitro |
Fluorometholone (25-100 nM; 12 hours, 24 hours) activates glucocorticoid receptors in conjunctival and corneal epithelial cells, increasing the expression of the MUC1, MUC4, MUC16, and MUC19 genes [1].
|
|---|---|
| Toxicity/Toxicokinetics |
Use of the medication during pregnancy and lactation ◉ Overview of use during lactation
There is currently no information regarding the use of fluorometholone eye drops during lactation. Due to limited absorption by the eye, fluorometholone eye drops are not expected to have any adverse effects on breastfed infants. After using the eye drops, to significantly reduce the amount of medication entering breast milk, press the tear duct at the corner of the eye for at least 1 minute, then blot away any excess medication with absorbent paper. ◉ Effects on breastfed infants As of the revision date, no relevant published information was found. ◉ Effects on breastfeeding and breast milk As of the revision date, no relevant published information was found. |
| References | |
| Additional Infomation |
Fluorometholone belongs to the class of glucocorticoids. Its structure is δ(1)-progesterone, with hydroxyl groups at positions 11β and 17, a methyl group at position 6α, and a fluorine group at position 9. It is used to treat inflammation of the palpebral conjunctiva, bulbar conjunctiva, cornea, and anterior segment of the eye that is sensitive to corticosteroids. It is an anti-inflammatory drug. Fluorometholone is a fluorinated steroid, 11β-hydroxy steroid, 20-oxo steroid, 3-oxo-δ(1),δ(4)-steroid, glucocorticoid, 17α-hydroxy steroid, and tertiary α-hydroxy ketone. It is functionally related to δ(1)-progesterone. It is a glucocorticoid, usually used as eye drops to treat allergic and inflammatory diseases of the eye. It has also been used topically to treat various skin diseases. (Excerpt from Martindale Pharmacopoeia, 30th edition, p. 732) Fluorometholone is a corticosteroid. The mechanism of action of fluorometholone is as a corticosteroid hormone receptor agonist. Fluorometholone is a synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Fluorometholone exerts its effects by interacting with cytoplasmic glucocorticoid receptors, subsequently activating glucocorticoid receptor-mediated gene expression. It induces the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Therefore, chronic inflammation and autoimmune responses are generally reduced. A glucocorticoid, commonly used as eye drops to treat allergic and inflammatory eye conditions. It has also been used topically to treat various skin conditions. (From Martindale Pharmacopoeia, 30th edition, p. 732) See also: Fluorometholone acetate (active ingredient); Fluorometholone; Sodium sulfacetamide (ingredient).
Indications For the treatment of inflammation of the palpebral conjunctiva, bulbar conjunctiva, cornea, and anterior segment of the eye in patients sensitive to corticosteroids. FDA label Mechanism of Action There is currently no universally accepted mechanism of action for ocular corticosteroids. However, the mechanism of action of corticosteroids is believed to be the induction of phospholipase A2-inhibiting proteins (collectively known as lipocortin). These proteins are presumed to control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The primary target of phospholipase A2 is the cytoplasmic glucocorticoid receptor. After receptor-receptor binding, the newly formed receptor-ligand complex translocates to the nucleus and binds to multiple glucocorticoid response elements (GREs) in the promoter regions of target genes. Subsequently, the DNA-bound receptor interacts with basal transcription factors, leading to increased expression of specific target genes. Pharmacodynamics Corticosteroids such as fluorometholone can inhibit inflammatory responses induced by a variety of factors and may delay or slow wound healing. They inhibit inflammation-related edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, collagen deposition, and scar formation. |
| Molecular Formula |
C22H29FO4
|
|---|---|
| Molecular Weight |
376.47
|
| Exact Mass |
376.204
|
| CAS # |
426-13-1
|
| Related CAS # |
Fluorometholone (Standard);426-13-1
|
| PubChem CID |
9878
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Melting Point |
292 - 303ºC
|
| Flash Point |
272.6±30.1 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
2.02
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
27
|
| Complexity |
787
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
|
| InChi Key |
FAOZLTXFLGPHNG-KNAQIMQKSA-N
|
| InChi Code |
InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
|
| Chemical Name |
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6alpha,11beta)-
|
| Synonyms |
NSC 33001 NSC-33001 NSC33001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~132.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6563 mL | 13.2813 mL | 26.5625 mL | |
| 5 mM | 0.5313 mL | 2.6563 mL | 5.3125 mL | |
| 10 mM | 0.2656 mL | 1.3281 mL | 2.6563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.